Studies have shown that trial participants lost an average of 10-15% of their body weight over one year
Ideal candidates for leading with NAD+: Patients over 40 experiencing persistent fatigue that does not resolve with sleep or lifestyle changes Individuals with metabolic syndrome, insulin resistance, or difficulty managing weight despite dietary effort Patients recovering from substance use, where NAD+ IV therapy has shown measurable benefit in reducing withdrawal symptoms and cravings High-performance athletes or executives seeking cognitive edge and faster physical recovery Patients with early neurodegenerative concerns who want evidence-supported mitochondrial support GHK-Cu Dosage and NAD+ Dosage: What Clinical Protocols Actually Use Dosing varies based on delivery route, patient body weight, and clinical goal
Storage The manufacturer recommends not exposing the product to direct light or heat sources, but keeping it cool and dark
The goal isnt to eat as little as possible
The immune system is essentially tricked into perceiving healthy bone and joint interfaces as damaged, prompting it to unnecessarily break them down
doi: 10.2337/dc17-1956 84 Pi-SunyerXAstrupAFujiokaKGreenwayFHalpernAKrempfMet al
